3 ms·
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
- melling 2y ago“The drug, lepodisiran, reduced levels of lipoprotein(a), or Lp(a), by an average of 93.9% versus placebo over six months after one or two 400 milligram doses”